- Børge G Nordestgaard, Robert A Hegele, Residual lipid risk in atherosclerotic cardiovascular disease, European Heart Journal, 2026;
Articolo di riferimento: https://doi.org/10.1093/eurheartj/ehag087 ;
- Galli, M., Abbate, A., Bonaca, M.P. et al. Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies. Nat Rev Cardiol (2026)
Articolo di riferimento: https://doi.org/10.1038/s41569-026-01249-z - Nauck AM et al. Glucagon-like receptor agonists and next-generation incretin-based
medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026 Feb
28;407(10531):892-908.
Articolo di riferimento: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02105-1 - Badve SV et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular
disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes
Endocrinol. 2025 Jan;13(1):15-28.
Articolo di riferimento: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00271-7 - Marx N et al. 2023 ESC Guidelines for the management of cardiovascular disease
in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140.
Articolo di riferimento: https://academic.oup.com/eurheartj/article/44/39/4043/7238227 - Vrints C et al. 2024 ESC Guidelines for the management of chronic coronary
syndromes: Developed by the task force for the management of chronic coronary
syndromes of the European Society of Cardiology (ESC) Endorsed by the
European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep
9;45(36):3415-3537.
Articolo di riferimento: https://academic.oup.com/eurheartj/article/45/36/3415/7743115 - ADA Standards of Care in Diabetes 2026. Pharmacologic Approaches to Glycemic
Treatment. Diabetes Care 2026;49(Supplement_1):S183–S215.
Articolo di riferimento: https://diabetesjournals.org/care/article/49/Supplement_1/S183/163934/9-
Pharmacologic-Approaches-to-Glycemic-Treatment - McGuirre DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk
Type 2 Diabetes. N Engl J Med. 2025 May 29;392(20):2001-2012.
Articolo di riferimento: https://www.nejm.org/doi/abs/10.1056/NEJMoa2501006 - Marso PS et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2
Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.
Articolo di riferimento: https://www.nejm.org/doi/10.1056/NEJMoa1607141 - Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with
Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121.
Articolo di riferimento: https://www.nejm.org/doi/10.1056/NEJMoa2403347 - Frias PJ et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0
mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised,
phase 3B trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574.
Articolo di riferimento: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00174-1 - Raveendra K et al. Glucagon-like peptide-1 receptor agonists for prevention of heart
failure events in type 2 diabetes and/or obesity. ESC Heart Fail. 2026 Mar
3;13(2):xvag091.
Articolo di riferimento: https://academic.oup.com/eschf/article/13/2/xvag091/8540500 - Kosiborod NM et al. Semaglutide in Patients with Heart Failure with Preserved
Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084.
Articolo di riferimento: https://www.nejm.org/doi/full/10.1056/NEJMoa2306963 - Kosiborod NM et al. Semaglutide in Patients with Obesity-Related Heart Failure and
Type 2 Diabetes. N Engl J Med. 2024 Apr 18;390(15):1394-1407.
Articolo di riferimento: https://www.nejm.org/doi/full/10.1056/NEJMoa2313917 - Butler J et al. Semaglutide versus placebo in people with obesity-related heart
failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and
STEP-HFpEF DM randomised trials. Lancet. 2024 Apr 27;403(10437):1635-1648.
Articolo di riferimento: https://www.thelancet.com/article/S0140-6736(24)00469-0 - Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without
Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232.
Articolo di riferimento: https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 - Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP
UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025
Nov;13(11):949-963.
Articolo di riferimento: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00226-8 - Smolderen KG et al. Association between semaglutide 2.4 mg and risk of
cardiovascular events in people with overweight or obesity without atherosclerotic
cardiovascular disease in the real-world: The SCORE – primary prevention study.
American Journal of Preventive Cardiology 2026. DOI: 10.1016/j.ajpc.2026.101521.
Articolo di riferimento: https://www.sciencedirect.com/science/article/pii/S2666667726001157 - Wilson L et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in
people with overweight or obesity in the real world (STEER). Diabetes Obes Metab.
2026 Mar;28(3):2403-2415.
Articolo di riferimento: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70436 - Tan X et al. Comparison of cardiovascular outcomes between once-weekly
semaglutide and dulaglutide in adults with type 2 diabetes and established
atherosclerotic cardiovascular disease in the United States. Diabetes Obes Metab.
2026 Apr;28(4):2661-2671.
Articolo di riferimento: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70440 - Mazhar F, Faucon AL, Fu EL, Szummer KE, Mathisen J, Gerward S, Reuter SB,
Marx N, Mehran R, Carrero JJ. Systemic inflammation and health outcomes in
patients receiving treatment for atherosclerotic cardiovascular disease. Eur Heart J.
2024 Nov 21;45(44):4719-4730. doi: 10.1093/eurheartj/ehae557.
Articolo di riferimento: - Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and
Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American
College of Cardiology. J Am Coll Cardiol. 2025 Sep 29:S0735-1097(25)07555-2.
Articolo di riferimento: https://www.sciencedirect.com/science/article/pii/S0735109725075552?ref=pdf_download&fr=RR-2&rr=9f68977ee91eee6e - Mazhar F, Capodanno D, Hjemdahl P, Sjölander A, Gerward S, Mathisen J, Plunde
O, Kunadian V, Jernberg T, Carrero JJ. Inflammatory and cholesterol risks and rates
of major cardiovascular events among patients with atherosclerotic cardiovascular
disease in routine care. Eur Heart J Open. 2026 Feb 17;6(2):oeag023.
Articolo di riferimento:
Ultime modifiche: lunedì, 4 maggio 2026, 17:42